When it comes to adolescents, treating obesity without first completing a psychiatric evaluation can sometimes cause more harm than good, says Sid Khurana, MD, DFAPA, DFAACAP, a board-certified psychiatrist, clinical assistant professor at the University of Nevada, Las Vegas School of Medicine, and medical director of Nevada Mental Health
is a co-inventor on intellectual property owned by Indiana University and licensed to Novo Nordisk
Substantial invested capital will be necessary to understand whether these novel targets and modalities will be successful in treating obesity
Although less than 5% of pancreatitis cases are drug-induced and tirzepatide appears to exhibit safety regarding pancreatitis risk [57], there is emerging evidence of a substantial risk associated with GLP-1 receptor agonists [58]
Glucagon-like Peptide-1 (GLP-1) is a hormone that helps regulate blood sugar levels and appetite